Docetaxel kombinációs kezeléssel (TAC) szerzett tapasztalataink az emlőrák adjuváns kemoterápiájában: BCIRG 001 randomizált, multicentrikus fázis III vizsgálat hazai eredményei

Magyar Onkologia

Volumn 47, Issue 2, 2003, Pages 141-148

  Katalin, Boér ^a,e   István, Láng ^b   Éva, Juhos ^b   Tamás, Pintér ^c   János, Szántó ^a,d  

^a Szent Margit Kórház Szülészeti és Nögyógyászati Osztály   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c I Belgyógyászati gasztroenterológiai Osztály   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e St Margit's Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874972376     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with nodenegative rapidly proliferating breast cancer. A randomized multicenter study. J Clin Oncol 18:3125-3134, 2000
2. Baki M. Taxotere-Herceptin kombinációaz emlo{double acute}rák kezelésében. Pathol Oncol Res Suppl 2:25-29, 2002 (in Hungarian)
3. Bonadonna G, Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Res 48:2314-2324, 1998
4. Chan S, Friedrich K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
5. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930-942, 1998
6. Early Breast Cancer Trialists Collaborative Group. 2000 analysis overview results. Fifth Meeting of the Early Breast Cancer Trialists Collaborative Group, Oxford, United Kingdom, September 21-23, 2000
7. Eckhardt S. A docetaxel hatása a daganatokra. Orvosi Hetilap 139:867-872, 1998
8. Fumoleau P, Chevalier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: A report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996
9. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Highlights. International consensus panel on treatment of primary breast cancer. J Natl Cancer Inst 90:1601-1608, 1998
10. Henderson CI. Adjuvant chemotherapy: Taxanes-The "pro" position. Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy of Breast Cancer, Bethesda, MD, November 1-3, 2000
11. Hudis CA, Seidman AD, Crown JPA, et al. Phase II pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
13. Lohrisch C, Di Leo A, Piccart MJ. Optimal adjuvant cytotoxic therapy for breast cancer. ASCO Educational Book pp. 61-70, 2001
14. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of Docetaxel versus Mitomycin C plus Vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413-1422, 1999
15. Nabholtz JM, Falkson D, Campos J, et al. A phase III trial comparing Doxorubicin and Docetaxel (AT) to Doxorubicin and Cyclophosphamide (AC) as first line chemotherapy for MBC. Proc Am Soc Clin Oncol 18:485a, 1999
16. Nabholtz JM, Mackey JR, Smylie M, et al. Final results of phase II study of docetaxel, doxorubicin and cyclophosphamide (TAC) as 1st line chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat 50:227, 1998
17. Nabholtz JM, Riva A. Taxane/Anthracycline combinations: Setting a new standard in breast cancer? The Oncologist 6(Suppl 3):5-12, 2001
18. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol (abstract No 141) 21:36a, 2002
19. Piccar MJ, Lohrisch C, Duchateau L, et al. Taxanes in the adjuvant setting: why not yet? J Natl Cancer Inst Monogr 30:88-95, 2001
20. Szántó J, Pintér T, Szántó J. Doxorubicin+docetaxel-, illeto{double acute}leg doxorubicin + cyclophosphamid-kezeléssel elérheto{double acute} eredmények távoli áttétet adó emlo{double acute}rákban. Orvosi Hetilap 142:723-726, 2001
21. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:422-428, 1996
22. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of EORTC-ECTG. Ann Oncol 5:527-532, 1994